These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21335482)

  • 1. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.
    Fogari R; Mugellini A; Zoppi A; Preti P; Destro M; Lazzari P; Derosa G
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):34-43. PubMed ID: 21335482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
    Fogari R; Derosa G; Ferrari I; Corradi L; Zoppi A; Lazzari P; Santoro T; Preti P; Mugellini A
    Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size.
    Fogari R; Zoppi A; Maffioli P; Mugellini A; Preti P; Perrone T; Derosa G
    Clin Cardiol; 2012 Jun; 35(6):359-64. PubMed ID: 22522403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients.
    Galzerano D; Di Michele S; Paolisso G; Tuccillo B; Lama D; Carbotta S; Cittadini A; Tedesco MA; Gaudio C
    J Renin Angiotensin Aldosterone Syst; 2012 Dec; 13(4):496-503. PubMed ID: 22546623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients.
    Du H; Fan J; Ling Z; Woo K; Su L; Chen S; Liu Z; Lan X; Zhou B; Xu Y; Chen W; Xiao P; Yin Y
    Hypertension; 2013 Apr; 61(4):786-92. PubMed ID: 23438932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.
    Celik T; Iyisoy A; Kursaklioglu H; Yilmaz MI; Kose S; Kilic S; Amasyali B; Demirkol S; Isik E
    Clin Cardiol; 2005 Jun; 28(6):298-302. PubMed ID: 16028466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
    Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
    Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
    J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.
    Gosse P; Schumacher H
    Hypertens Res; 2014 Feb; 37(2):151-7. PubMed ID: 24048485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.
    Delles C; Raff U; Mimran A; Fauvel JP; Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 Dec; 21(12):1330-6. PubMed ID: 18989258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients.
    Guthrie RM; Dahlöf B; Jamerson KA; Olvera R; Seeber M; Schumacher H; Oigman W
    Curr Med Res Opin; 2011 Oct; 27(10):1995-2008. PubMed ID: 21905967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
    Sharma AM; Bakris G; Neutel JM; Littlejohn TW; Kobe M; Ting N; Ley L
    Clin Ther; 2012 Mar; 34(3):537-51. PubMed ID: 22386829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
    Yamagishi S; Takenaka K; Inoue H
    Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis.
    Pan G; Zhou X; Zhao J
    Cardiovasc Ther; 2014 Aug; 32(4):184-8. PubMed ID: 24645740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
    Lamarre-Cliche M; de Champlain J; Lacourcière Y; Poirier L; Karas M; Larochelle P
    Am J Hypertens; 2005 Jan; 18(1):56-64. PubMed ID: 15691618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.